MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Cytokinetics Inc

Cerrado

SectorSanidad

40.29 7.44

Resumen

Variación precio

24h

Actual

Mínimo

37.5

Máximo

43.53

Métricas clave

By Trading Economics

Ingresos

11M

-150M

Ventas

16M

17M

BPA

-1.26

Margen de beneficios

-886.276

Empleados

498

EBITDA

13M

-125M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+117.15% upside

Dividendos

By Dow Jones

Próximas Ganancias

7 may 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-723M

5.1B

Apertura anterior

32.85

Cierre anterior

40.29

Noticias sobre sentimiento de mercado

By Acuity

20%

80%

41 / 386 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Cytokinetics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

5 jun 2024, 15:26 UTC

Adquisiciones, fusiones, absorciones

Cytokinetics CEO Says Board Would Have Backed Actionable Buyout

5 jun 2024, 14:14 UTC

Adquisiciones, fusiones, absorciones

Cytokinetics: Board, Management Would Never Stand in Way of Value-Maximizing Transaction >CYTK

5 jun 2024, 14:14 UTC

Adquisiciones, fusiones, absorciones

Cytokinetics CEO: Board Would Have Supported Actionable Proposal in Best Interests of Shareholders >CYTK

5 jun 2024, 14:14 UTC

Adquisiciones, fusiones, absorciones

WSJ Reported in January That Novartis Backed Away From Pursuit of Cytokinetics >CYTK

5 jun 2024, 14:14 UTC

Adquisiciones, fusiones, absorciones

Cytokinetics CEO: Other Party Didn't Move Forward With Acquisition >CYTK

5 jun 2024, 14:14 UTC

Adquisiciones, fusiones, absorciones

Cytokinetics CEO: Board Was Supportive of Moving Forward on Deal on Terms Company Believed Would Be Mutually Acceptable >CYTK

5 jun 2024, 14:14 UTC

Adquisiciones, fusiones, absorciones

Cytokinetics CEO: Previously Held Good-Faith Talks With Another Party on Acquisition of Company >CYTK

Comparación entre iguales

Cambio de precio

Cytokinetics Inc previsión

Precio Objetivo

By TipRanks

117.15% repunte

Estimación a 12 Meses

Media 81.43 USD  117.15%

Máximo 120 USD

Mínimo 62 USD

De acuerdo con 17 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Cytokinetics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

17 ratings

16

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

N/A / 42.705Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Strong Bearish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

41 / 386 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Cytokinetics Inc

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. It develops small molecule drug candidates primarily engineered to impact muscle function and contractility. The company's drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. The company has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.